TAIVEX THERAPEUTICS INC.
Taivex has proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions. Hec1 was found to be over-expressed in many cancer cells, and the phosphorylation of Hec1 by Nek2 is critical for proper mitotic progress and chromosome segregation. Interruption of Hec1-Nek2 interaction results in mitotic defects, which lead to cell death. Hec1-Nek2 interactions regulate key events in the progression of human tumors, and therefore are attractive molecule targets for the development of new anti-cancer drugs.
TAIVEX THERAPEUTICS INC.
Social Links:
Industry:
Biotechnology
Founded:
2010-01-01
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.taivex.com
Status:
Active
Contact:
+886-2-2655-8300
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Analytics WordPress LetsEncrypt Global Site Tag
Similar Organizations
Panion & BF Biotech Inc.
Panion & BF Biotech Inc. is a biotech pharmaceutical company with diversified operations
Official Site Inspections
http://www.taivex.com Semrush global rank: 6.17 M Semrush visits lastest month: 1.12 K
- Host name: 61-222-164-105.hinet-ip.hinet.net
- IP address: 61.222.164.105
- Location: Taiwan
- Latitude: 23.5
- Longitude: 121
- Timezone: Asia/Taipei
More informations about "Taivex Therapeutics Inc."
Taivex Therapeutics Inc. - Crunchbase Company …
Taivex Therapeutics Inc. is a proprietary technology platforms to identify compounds that inhibit the Hec1-Nek2 interactions See details»
Taivex Therapeutics Corporation Company Profile - Dun
Find company research, competitor information, contact details & financial data for Taivex Therapeutics Corporation of Taipei City, Taipei. Get the latest business insights from Dun & … See details»
癌症新藥開發公司 | 泰緯生命科技股份有限公司 - Taivex
泰緯生命科技股份有限公司於 99 年2 月在台灣台北創立，由美國加州的 Taivex, LLC 與中國石油化學工業開發股份公司共同投資，泰緯專注於癌症新藥開發，挑戰當前仍未被滿足的醫療需求 … See details»
Taivex Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Jun 22, 2025 Taivex has developed exclusive technology platforms designed to identify compounds that can inhibit the interactions between Hec1 and Nek2. Hec1 is known to be … See details»
Taivex Therapeutics - 2025 Company Profile - Tracxn
Apr 25, 2025 Taivex Therapeutics is an unfunded company based in Taipei (Taiwan), founded in 2010. It operates as a Developing small molecule inhibitors of Hec1-Nek2 interactions for the … See details»
Cancer drug development company | Taivex Therapeutics …
Taivex is dedicated to the pre-clinical and clinical development of new drugs for anti-cancer target therapies to fulfill the unmet medical needs. See details»
Taivex Therapeutics Corp. - BioCentury Company Profiles - BCIQ
Taivex Therapeutics Corp. - BioCentury Company Profiles for the biopharma industry See details»
Taivex Therapeutics, Inc.:Company Profile & Technical Research ...
Mar 3, 2023 Taivex Therapeutics, Inc. is a company that provides Chromosome segregation, Phosphorylation, Human tumor and more. Taivex Therapeutics, Inc. is headquartered in China … See details»
NHRI Enters Technology Transfer Agreement of DBPR186 with …
Jan 5, 2022 National Health Research Institutes (NHRI) and Taivex Therapeutics Corp (Taivex) have signed the technology transfer agreement in September, 2021. Taivex has granted the … See details»
Contact Us | Cancer drug development company - Taivex
Taivex Therapeutics Corporation. Co., Ltd 2025 © All rights reserved. 網頁設計公司：振作雲科技 See details»
| 癌症新藥開發公司 | 泰緯生命科技股份有限公司
105台北市松山區東興路12號2樓 TEL：02-27486200 FAX：02-27486208 MAIL：[email protected] 關於泰緯 公司簡介 沿革里程碑 營運模式 組織架構 新藥產品 See details»
NHRI licenses DBPR216, an anti-cancer developmental drug …
Apr 17, 2019 The National Health Research Institutes (NHRI) and Taivex Therapeutics Corp. (Taivex) are pleased to announce the technology transfer of DBPR216, a potential anti-cancer … See details»
News | Cancer drug development company - Taivex
Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will further evaluate the safety and … See details»
Our Products | Cancer drug development company - Taivex
Copyright © 2025 Cancer drug development company | Taivex Therapeutics Corporation | Powered by Astra WordPress Theme See details»
Taivex Therapeutics, Inc. (泰纬生命科技股份有限公司) - 药物管线_ …
May 7, 2025 了解Taivex Therapeutics, Inc. (泰纬生命科技股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的5项临床试验, 1篇新闻，疾病领域:肿瘤，免疫系统疾病，血液及淋 … See details»
癌症新藥開發公司 | 泰緯生命科技股份有限公司 - Taivex
105台北市松山區東興路12號2樓 TEL：02-27486200 FAX：02-27486208 MAIL：[email protected] 關於泰緯 公司簡介 沿革里程碑 營運模式 組織架構 新藥產品 See details»
T-1101 Receives TFDA Approval for Phase II Clinical Trial
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials. The study will further … See details»
最新消息 | 癌症新藥開發公司 | 泰緯生命科技股份有限公司
泰緯生技宣布，旗下新藥 T-1101 已進一步獲得台灣衛生福利部食品藥物管理署（TFDA）核准，啟動臨床二期試驗。此次試 … See details»
T-1201 | Cancer drug development company - Taivex
T-1201 is a First-in-Class novel small molecule drug conjugate (SMDC) oncology drug. Its’ mechanism was similar with antibody drug conjugate. T-1201 specific target the cell surface … See details»